The estimated Net Worth of Chemical Co., Ltd.Sumitomo ... is at least $495 million dollars as of 10 March 2023. Chemical Sumitomo owns over 51,599,200 units of Urovant Sciences Ltd stock worth over $495,078,283 and over the last 5 years Chemical sold UROV stock worth over $0.
Sign up
Chemical Sumitomo UROV stock SEC Form 4 insiders trading
Chemical has made over 42 trades of the Urovant Sciences Ltd stock since 2020, according to the Form 4 filled with the SEC. Most recently Chemical bought 51,599,200 units of UROV stock worth $1,393,178,400 on 10 March 2023.
The largest trade Chemical's ever made was buying 51,599,200 units of Urovant Sciences Ltd stock on 10 March 2023 worth over $1,393,178,400. On average, Chemical trades about 1,319,419 units every 26 days since 2020. As of 10 March 2023 Chemical still owns at least 45,798,176 units of Urovant Sciences Ltd stock.
You can see the complete history of Chemical Sumitomo stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Urovant Sciences Ltd
Over the last 6 years, insiders at Urovant Sciences Ltd have traded over $0 worth of Urovant Sciences Ltd stock and bought 22,782,569 units worth $411,146,115 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... et Andrew Lo. On average, Urovant Sciences Ltd executives and independent directors trade stock every 6 days with the average trade being worth of $6,293,420. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 19 February 2020, trading 103,250 units of UROV stock currently worth $1,350,510.
What does Urovant Sciences Ltd's logo look like?
Complete history of Chemical Sumitomo stock trades at Myovant Sciences Ltd et Urovant Sciences Ltd
Urovant Sciences Ltd executives and stock owners
Urovant Sciences Ltd executives and other stock owners filed with the SEC include:
-
Cornelia Haag-Molkenteller,
Chief Medical Officer of USI -
Bryan Smith,
General Counsel - USI -
Michael McFadden,
Chief Commercial Officer -
Christine Ocampo,
Senior Vice President, Chief Accounting Officer, Principal Accounting Officer -
Kenton Stewart,
Senior Vice President of Market Access -
Walt Johnston,
Senior Vice President of Commercial -
James Hindman,
Director -
Shigeyuki Nishinaka,
Director -
Ajay Bansal,
Chief Financial Officer, Senior Vice President - Business Development, Principal Financial Officer -
Myrtle Potter,
Chairman of the Board -
James Robinson,
Principal Executive Officer, Director -
Pierre Legault,
Independent Director -
Sef Kurstjens,
Independent Director -
Holdings Ltd.Dexcel Pharma ...,
-
Associates Gp Llcqvt Fund V...,
-
Patrick Machado,
-
Frank Torti,
Director -
Global Investors Lp Viking ...,
-
Investments (Uk) Ltd Soft B...,
-
Nori Ebersole,
SVP&CHRO-Urovant Sciences,Inc. -
Global Performance Llc Viki...,
-
Sciences Ltd. Roivant,
10% owner -
Andrew Lo,
-
Global Performance Llc Viki...,
-
Associates Gp Llcqvt Financ...,
-
Chemical Co., Ltd.Sumitomo ...,
-
Keith Katkin,
PEO;CEO/Urovant Sciences, Inc.